Pfizer expects to sell $32 billion of its Covid-19 shots and $22 billion of its antiviral coronavirus treatment pill Paxlovid.
Highlights
- Pfizer’s fourth-quarter revenue more than doubled overall to $23.84 billion year-over-year, driven by $12.5 billion in sales of its Covid vaccine.
- Pfizer CEO Albert Bourla said sales of Paxlovid could be higher than the company’s guidance, but the expectations are based on deals signed or close to being signed.
- The company’s share was down more than 5.7% in morning trading.
- On an unadjusted basis, Pfizer profit increased more than fourfold to $3.39 billion from $847 million during the same three months in 2020.
- Pfizer expects $98 billion to $102 billion in revenue for 2022.